Paris, December 21. 2020. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announces today that an independent Data Monitoring Committee (DMC) recommends continuation of the Phase IIa study of nangibotide for the treatment of severe forms of COVID-19 hospitalized in intensive care units (ICU). The DMC was composed of unblinded external medical experts and based its decision on a pre-planned interim analysis of safety. This positive decision will allow Inotrem and its partners, the CHRU of Nancy and the CHU of Limoges, to carry on without modification its Phase IIa trial.